Research and Grants | The Cure Starts Now

The Cure Starts Now has funded $18,068,037 in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 117 grants at over 100 hospitals in 15 countries.


Massachusetts General Hospital – $50,000

Amount
$50,000.00
Date
November 2021

Targeted Protein Degradation for DIPG Therapy

CONNECT2007 - $385,794

Amount
$385,794.00
Date
September 2021

Phase I/II Study of Lutathera in Pediatric and Young Adult Patients with Recurrent and/or Progressive High-Grade Central Nervous System (CNS) Tumors and Meningiomas which Express Somatostatin Type 2A Receptors and Demonstrate Uptake on DOTATATE

CONNECT2109A - $705,764

Amount
$705,764.00
Date
September 2021

CONNECT2109A: A molecularly-guided phase II study of ribociclib and everolimus in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG)

CONNECT Consortium - $278,619

Amount
$278,619.00
Date
September 2021

Immuno-Modulation to Treat Poor-Prognosis Pediatric Brain Tumors

Institute of Cancer Research – $113,747

Amount
$113,747.00
Date
September 2021

Co-Culture Disruptor Screens to Target Cell-Cell Interactions in DMG

Institute of Cancer Research – $498,716

Amount
$498,716.00
Date
September 2021

Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG) - An International Connect Consortium Preclinical / Clinical

Sydney Children’s Hospital – $195,327

Amount
$195,327.00
Date
September 2021

Phase I/II Study of Oral DFMO and AMXT1501 for DIPG/DMG

Children’s Hospital of Colorado – $200,000

Amount
$200,000.00
Date
September 2021

Multimodality, Combination Treatment Strategy for DIPG/DMG